This study is about using a medicine called atovaquone to treat a kind of cancer called platinum-resistant ovarian cancer. This cancer doesn't respond well to usual treatments. Atovaquone is normally used to fight off certain infections and is part of a group of medicines known as antiprotozoal agents. These medicines work by stopping tiny germs called protozoa from growing, which can cause illnesses like pneumonia. In this study, researchers want to see if atovaquone can help improve cancer treatment results compared to regular methods.

• Participants will take atovaquone by mouth during the study.
• The study includes tests like CT scans and biopsies to monitor progress.
• After treatment, follow-ups will occur for 30 days and then every 6 months.

To join, patients must be 18 or older and have certain types of ovarian cancer. They can't be pregnant, in prison, or unable to make decisions. The study is open to people who speak other languages and those from different hospitals.